Latest Office News

ACDC Metals enters FY27 with a larger Nevada exploration footprint and a 10-year licence over its Goschen Central rare earths project, but a sharply higher annual loss and ongoing funding needs remain part of the picture. The company plans up to 2,500 metres of reverse-circulation drilling at Mount Jackson in Q4 CY2026.

AnteoTech has received $1.905 million from the Australian R&D Tax Incentive, providing fresh cash for its battery materials and life sciences commercialisation efforts. The rebate relates to eligible research conducted during the 2026 financial year.

Melbana Energy’s Block 9 project remains on care and maintenance after a partner default and US sanctions on CUPET, despite improved geological understanding from Amistad-2. The company ended FY2026 with $472,504 in cash and warned that additional funding is required to continue.

Neuren says its partner Acadia has received a US Notice of Allowance for a trofinetide patent that could protect weight-banded dosing through 28 March 2041. The patent has not yet formally issued, but the allowance could extend US protection by almost five years beyond the existing method-of-use patent.

TradeWindow is targeting 13% to 18% revenue growth in FY27 and expects to approach EBITDA breakeven, while preparing to shift its primary listing from the NZX to the ASX. The freight software company also reported rising recurring revenue, stronger customer economics and NZ$4.0 million in cash at 30 June 2026.

SciDev Limited (ASX:SDV) finished FY26 with a sharp annual earnings decline, but a leaner business and stronger second-half performance offer a potential reset. Revenue fell 17% and underlying EBITDA dropped 49%, while the company exited loss-making international operations and rebuilt net cash to $6.8 million.

Mantle Minerals reported a $12.50 million FY2026 profit after selling Mt Roe Mining to Northern Star for $13.5 million, while continuing operations remained loss-making. The company ended the year with $5.50 million in cash and is redirecting capital towards Yule River and Carlton Hill exploration.

Cynata Therapeutics (ASX:CYP) has reported a $9.25 million loss, negative net assets and a material uncertainty over going concern after its two major clinical trials failed to demonstrate efficacy. The company has since cut its workforce to zero, shifted management to the board and secured a $600,000 R&D tax incentive loan while it considers the future of its Cymerus platform.

AUCyber has added approximately $1.34 million in annual recurring revenue from two Australian university contracts, including a new 12-month deal with the University of New England worth more than $600,000 a year. The cybersecurity provider is also bidding for a separate university engagement valued at about $5.5 million, although that opportunity remains uncontracted.

Otto Energy plans to return approximately A$20 million to shareholders after consolidating its shares 100:1, with the proposed payment set at A$0.417 per post-consolidation share. The proposals require approval at the company’s 13 November 2026 AGM and remain subject to an outstanding ATO tax ruling.

Challenger Gold has locked in US$24 million through five-year unsecured convertible debentures to advance its Hualilán project, with a further US$6.3 million potentially available. The financing carries an 11% coupon and only part of the proceeds is unconditional, leaving shareholder approval and a much larger funding requirement ahead.

EBR Systems has completed the FDA’s pre-approval inspection of its new Santa Clara manufacturing facility, receiving two Form 483 observations. The company says it expects to correct them in the fourth quarter and still anticipates approval by year-end, although the FDA has not yet made its final determination.